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 Chapter 4 
 Best Practices in Manual Annotation with the Gene 
Ontology 
 Sylvain  Poux and  Pascale  Gaudet 
 Abstract 
 The Gene Ontology (GO) is a framework designed to represent biological knowledge about gene prod-
ucts’ biological roles and the cellular location in which they act. Biocuration is a complex process: the body 
of scientifi c literature is large and selection of appropriate GO terms can be challenging. Both these issues 
are compounded by the fact that our understanding of biology is still incomplete; hence it is important to 
appreciate that GO is inherently an evolving model. In this chapter, we describe how biocurators create 
GO annotations from experimental fi ndings from research articles. We describe the current best practices 
for high-quality literature curation and how GO curators succeed in modeling biology using a relatively 
simple framework. We also highlight a number of diffi culties when translating experimental assays into GO 
annotations. 
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1  Background 
 Biological databases have become an integral part of the tools 
researchers use on a daily basis for their work. GO is a controlled 
vocabulary for the description of biological function, and is used 
to annotate genes in a large number of genome and protein data-
bases. Its computable structure makes it one of the most widely 
used resources. Manual annotation with GO involves biocurators, 
who are trained to reading, extracting, and translating experi-
mental fi ndings from publications into GO terms. Since both the 
scientifi c literature and the GO are complex, novice biocurators 
can make errors or misinterpretations when doing annotation. 
Here, we present guidelines and recommendations for best prac-
tices in manual annotation, to help curators avoid the most com-
mon pitfalls. These recommendations should be useful not only 
to biocurators, but also to users of the GO, since the understand-
ing of the curation process should help understand the meaning 
of the annotations. 
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 Our understanding of the world is built by observation and exper-
imentation. The overall process of the scientifi c method involves 
making hypotheses, deriving predictions from them, and then 
carrying out experiments to test the validity of these predictions. 
The results of the experiments are then used to  infer whether the 
prediction was true or not [ 1 ]. Hypotheses are tested, validated, 
or rejected, and the combination of all the experiments contrib-
utes to uncovering the mechanism underlying the process being 
studied (Fig.  1 ).
 Examples of experiments include testing an enzymatic activity 
in vitro using purifi ed reagents, measuring the expression level of 
a protein upon a given stimulus, or observing the phenotypes of 
an organism in which a gene has been deleted by molecular genet-
ics techniques. Different inferences can be made from the same 
experimental setup depending on the hypothesis being tested. 
Thus, the conclusions that can be derived from individual experi-
ments may vary, depending on a number of factors: they depend 
on the current state of knowledge, on how well controlled the 
experiment is, on the experimental conditions, etc. It also hap-
pens that the conclusions from a low-resolution experiment are 
partially or completely refuted when better techniques become 
available. These factors are inherent to empirical studies and 
must be taken into account to ensure correct interpretation of 
experimental results. 











 Fig. 1  How the scientifi c method is used to test and validate hypotheses 
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 GO is a framework to describe the roles of gene products across all 
living organisms [ 2 ] ( see also Chap.  2 , [ 3 ]). The ontology is divided 
into three branches, or aspects: Molecular Function (MF) that cap-
tures the biochemical or molecular activity of the gene product; 
Biological Process (BP), corresponding to the wider biological 
module in which the gene product’s MF acts; and Cellular 
Component (CC), which is the specifi c cellular localization in 
which the gene product is active. 
 The association of a GO term and a gene product is not explic-
itly defi ned, but implicitly means that the gene product  has an 
activity or a molecular role (MF term),  directly participates in a 
process (BP), and the function takes place  in a specifi c cellular 
localization (CC) [ 2 ]. Therefore, transient localizations such as 
endoplasmic reticulum and Golgi apparatus for secreted proteins 
are not in the scope of GO. Biological process is the most challeng-
ing aspect of the GO to capture, in part because it models two 
categories of processes:  subtypes : “mitotic DNA replication” 
(GO:1902969) is a particular type of “nuclear DNA replication” 
(GO:0033260), and  sub-processes : mitotic DNA replication is a step 
of the “cell cycle” (GO:0000278). These two classifi cation axes are 
distinguished by “is a” and “part of” relations with their parents, 
respectively. Gene products can be annotated using as many GO 
terms as necessary to completely describe its function, and the GO 
terms can be at varying levels in the hierarchy, depending on the 
evidence available. If a gene product is annotated to any particular 
term, then the annotations also hold for all the is-a and part-of par-
ent terms. Annotations to more granular terms carry more infor-
mation; however the annotation cannot be any deeper than what is 
supported by the evidence. 
 The complexity of biology is refl ected in the GO: with 40,000 
different terms [ 4 ], learning to use the GO can be compared to 
learning a new language. As when learning a language, there are 
terms that are closely related to those we are familiar with, and oth-
ers that have subtle but important differences in meaning. The GO 
defi nes each term in two complementary ways: fi rst by a textual 
defi nition intended to be human readable. Secondly, the structure 
of the ontology as determined by relationships of terms between 
each other is also a way by which terms are defi ned these can be 
utilized for computational reasoning. 
 There are two general methods for assigning GO terms to gene 
products. The fi rst is based on  experimental evidence , and involves 
detailed reading of scientifi c publications to capture knowledge 
about gene products. Biocurators browse the GO ontologies to 
associate appropriate GO term(s) whose defi nition is consistent 
with the data published for the gene product.  See Chaps.  3 [ 5 ] and 
 17 [ 6 ], for a description of the elements of an annotation. Expert 
curation based on experiments is considered the gold standard of 
1.2  Knowledge 
Representation Using 
Ontologies
1.3  Methods 
for Assigning 
GO Annotations
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functional annotation. It is the most reliable and provides strong 
support for the association of a GO term with a gene product. 
 The second method involves making  predictions on the pro-
tein’s function and subcellular localization, most often with meth-
ods relying on sequence similarity. Although not detailed in this 
chapter, prediction methods are highly dependent on annotations 
based on experiments. Indeed, all methods to assign annotations 
based on sequence similarity are more or less directly derived from 
knowledge that has been acquired experimentally; that is, at least 
one related protein must have been tested and shown to have a 
given function for that information to be propagated to other pro-
teins. Hence, the accurate assignment of GO classes to gene prod-
ucts based on experimental results is crucial, since many further 
annotations depend on their accuracy. 
2  Best Practices for High-Quality Manual Curation 
 Similar to the process by which experimental results get trans-
lated into a model of the biological phenomenon being investi-
gated, biocurators take the conclusions from the investigation 
and convert it into the GO framework. Thus, the same assay may 
lead to different interpretations depending on the question being 
tested. 
 As shown in Table  1 , an assay must be interpreted in the wider 
context of the known roles of the protein, and how directly the 
assay assesses the protein’s role in the process under investigation. 
Here, several experiments are described in which the readout is 
DNA fragmentation upon apoptotic stimulation, but that lead to 
different annotations. DFFB (UniProtKB O76075) is annotated to 
“apoptotic DNA fragmentation” (GO:0006309) because the pro-
tein is also known to be a nuclease. CYCS (UniProtKB P99999) is 
annotated to caspase activation (“activation of cysteine-type endo-
peptidase activity involved in apoptotic process” (GO:0006919)) 
because a direct role has been shown using an in vitro assay. 
However CYCS is not annotated to “apoptotic DNA fragmenta-
tion” (GO:0006309) despite the observation that removing it 
from cells prevents DNA fragmentation, since the activity of CYCS 
occurs before DNA fragmentation. Any step that takes place after-
wards will inevitably fail to happen, but this does not imply partici-
pation in this downstream sequence of molecular events. Finally, 
the FOXL2 (UniProtKB P58012) transcription factor has a posi-
tive effect on the occurrence of apoptosis, by an unknown mecha-
nism, so it is annotated to “positive regulation of apoptotic process” 
(GO:0043065). This is where the curator’s knowledge is critical 
and provides most added value over, e.g., machine learning and 
text mining
2.1  GO Inference 
Process
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 With more than 500,000 records indexed yearly in PubMed, it is 
not possible for the GO to comprehensively represent all the avail-
able data on every protein. To address this, a careful prioritization 
of both articles and proteins to annotate is done. The publications 
from which information is drawn are selected to accurately repre-
sent the current state of knowledge. Accessory fi ndings and non- 
replicated data are not systematically annotated; confi rmation or at 
least consistency with fi ndings from several publications is invalu-
able to accurately describe the function of a gene product. 
 Focusing on a topic allows the curator to construct a clear pic-
ture of the protein’s role and makes it easier to make the best deci-
sions when capturing biological knowledge as annotations. Reading 
different publications in the fi eld helps to resolve issues and select 
terms with more confi dence. Existing GO annotation in proteins 
that participate in the same biological process is also helpful to 
2.2  Needles 
and Haystacks
 Table 1 
 GO inference process, from the hypothesis in the paper to the assay and result, and to the inference 
of a GO function or role 
 Protein  Known roles  Hypothesis  Assay → Result  Conclusion → GO  Reference 
 DDFB 
(O76075) 
 DNase  The nuclease 
activity of DDFB 




 Apoptotic DNA 
fragmentation 
 →Increased in the 
presence of 
DDFB 




 →Apoptotic DNA 
fragmentation 
(GO:0006309) 






 CYCS triggers the 
activation of 
caspase-3 
 Apoptotic DNA 
fragmentation 
 →Decreased upon 
immunodepletion 
of CYCS 7 
 CYCS  directly 
activates 
caspase-3 







 [ 8 ] 
 Purifi ed CYCS 








 Mutations in 
FOXL2 are 
known to cause 
premature 
ovarian failure, 
which may be 
due to increased 
apoptosis 
 Apoptotic DNA 
fragmentation 
 →Increased in the 
presence of 
FOXL2 
 FOXL2 increases 







 [ 9 ] 
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decide on how best to represent the experimental data with the GO. 
On the other hand, without the broader context of the research 
domain, some papers may be misleading: fi rst, as more data accu-
mulate, a growing number of contradictory or even incorrect 
results are found in the scientifi c literature. Second, the way knowl-
edge evolves occasionally obsoletes previous fi ndings. Curators use 
their expertise to assess the scientifi c content of articles and avoid 
these pitfalls [ 10 ]. 
 The level of granularity of an annotation is dictated by the evidence 
supporting it. A good illustration is provided by ADCK3 protein in 
human (UniProtKB Q8NI60), an atypical kinase containing a pro-
tein kinase domain involved in the biosynthesis of ubiquinone, and 
an essential lipid-soluble electron transporter. Although it contains 
a protein kinase domain, it is unclear whether it acts as a protein 
kinase that phosphorylates other proteins in the CoQ complex or 
acts as a lipid kinase that phosphorylates a prenyl lipid in the ubi-
quinone biosynthesis pathway [ 11 ]. While it would be tempting to 
conclude that the protein has “protein kinase activity” 
(GO:0004672) from the presence of the protein kinase domain, 
the more general term “kinase activity” (GO:0016301) with no 
specifi cation of the potential substrate class (lipid or protein) is 
more appropriate. 
 Annotations focus on capturing experiments that are biologically 
relevant. Thus, substrates, tissue, or cell-type specifi city are anno-
tated only when the data indicates the physiological importance of 
these parameters. One diffi culty is that it is not always possible to 
distinguish between  experimental context and  biological context, 
which can potentially result in GO terms being assigned as if they 
represented a specifi c role or under specifi c conditions, while in 
fact this only refl ects the experimental setup and does not have real 
biological signifi cance. For example, the activity of E3 ubiquitin 
protein ligases is commonly tested by an in vitro autoubiquitina-
tion assay. While convenient, the assay is not conclusive with 
respect to the “protein autoubiquitination” (GO:0051865) 
in vivo. In the absence of additional data, only the term “ubiquitin 
protein ligase activity” (GO:0061630) should be used. Similarly, 
the cell type in which a function was tested does not imply that the 
cell type is relevant for the function; any hint that the protein is 
studied outside its normal physiological context (such as overex-
pression) should be carefully taken into consideration. 
 Downstream effects, as well as readouts (discussed above in 
Subheading  2.1 ), can lead to incorrect annotations if they are 
directly assigned to a gene product playing a role many steps 
 further. Here we use downstream as “occurring after,” with no 
implication on the  direct sequentiality of the events. 
2.3  How Low Can 
You Go: Deciding 
on the Level 
of Granularity 
of an Annotation
2.4  Less Is More: 
Avoiding 
Over- Interpretation
2.4.1  Biological 
Relevance of Experiments
2.4.2  Downstream 
Effects
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 Gene products that play housekeeping functions or function 
upstream of important signaling pathways have many indirect 
effects and pose a challenge for annotation. This can be illustrated 
by proteins that mediate chromatin modifi cation. Histone tails are 
posttranslationally modifi ed by a complex set of interdependent 
modifi cations. For instance, histone H2B monoubiquitination at 
Lys-120 (H2BK120ub) is a prerequisite for the methylation of 
histone H3 at Lys-4 and Lys-79 (H3K4me and H3K79me, respec-
tively) (Fig.  2 ). RNF20 (UniProtKB Q5VTR2), an E3 ubiquitin 
ligase that mediates H2BK120ub, therefore indirectly promotes 
H3K4me and H3K79me methylation [ 12 ]. Thus, the annotation 
of enzymes that modify histone tails is limited to the primary 
function of the enzyme (“ubiquitin-protein ligase activity” 
(GO:0004842) and “histone H2B ubiquitination” (GO:0033523), 
in this case), while the further histone modifi cations are only anno-
tated to the proteins mediating these modifi cations.
 A similar approach is taken for cases where the experimental 
readout is also a GO term. Examples of this include DNA fragmen-
tation assays to measure apoptosis, and MAPK cascade to measure 
the activation of an upstream pathway. Proteins that are involved in 
signaling leading to apoptosis do not mediate or  participate in 
DNA fragmentation, but their addition or removal causes changes 
in the amount of DNA fragmentation upon apoptotic stimulation. 
In other words, the effect of a protein on a specifi c readout can be 
very indirect. Whenever possible, annotation of these very specifi c 
terms (“apoptotic DNA fragmentation” (GO:0006309), “MAPK 
cascade” (GO:0000165)) is limited to cases where there is evidence 
of a molecular function supporting a direct implication in the pro-
cess. If that information is not available, the annotation is made to 
a more general term, such as “apoptotic process” (GO:0006915) 
or “intracellular signal transduction” (GO:0035556), for instance. 
 One common method to determine the function or process of a 
gene is mutagenesis. However, interpreting the results from mutant 
phenotypes is very diffi cult, as the effects caused by the absence or 








 Fig. 2  Monoubiquitination of histone H2B (H2BK120ub) promotes methylation of 
histone H3 (H3K4me and H3K79me) 
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knockdown or “add back” experiments (in which proteins are 
either overexpressed or added to a cellular extract) cannot demon-
strate the  participation of a protein in a process, only its require-
ment for the process to occur. Inferring a participatory role would 
be an over-interpretation of the results. A striking illustration of 
this can be made with housekeeping genes, such as those involved 
in transcription and translation: knockouts in these proteins (when 
not lethal) can be pleiotropic and affect essentially all cellular pro-
cesses. It would be both inaccurate and overwhelming for curators 
to annotate these gene products to every cellular process impacted. 
The more prior knowledge we have about a protein’s function, in 
particular its biochemical activity, the more accurate we can be 
when interpreting a phenotype. 
 Phenotypes caused by gene mutations are of great interest, not 
only to try to understand the function of proteins, but also to pro-
vide insights into mechanisms leading to disease. The scope of the 
GO, though, is to capture the  normal function of proteins. There 
are phenotype ontologies for human—HPO [ 13 ], mouse—MP 
[ 14 ] and other species that allow capturing phenotype in a struc-
ture that is more relevant to this type of data. 
 One limitation of the GO is that main functions and secondary 
roles are not explicitly encoded, so that this information is diffi cult 
to fi nd. For example, enzymes may have different substrates: in 
some cases, the substrate specifi city is driven by the biological con-
text, but in other cases by the experimental conditions. While some 
activities represent the main function of the enzyme, others are 
secondary or can be limited to very specifi c conditions. 
 A good example is provided by the CYP4F2 enzyme 
(UniProtKB Q9UIU8), a member of the cytochrome P450 family 
that oxidizes a variety of structurally unrelated compounds, 
including steroids, fatty acids, and xenobiotics. In vivo, the enzyme 
plays a key role in vitamin K catabolism by mediating omega- 
hydroxylation of vitamin K1 (phylloquinone), and menaquinone-4 
(MK-4), a form of vitamin K2 [ 15 ,  16 ]. While hydroxylation of 
phylloquinone and MK-4 probably constitutes the main activity of 
this enzyme since this activity has been confi rmed by several in vivo 
assays, CYP4F2 also shows activity towards other related sub-
strates, such as arachidonic acid omega and leukotriene-B [ 10 ] 
omega [ 17 – 21 ]. Clearly vitamin K1 and MK-4 are the main physi-
ological substrates of CYP4F2, but since it is plausible that the 
enzyme also acts on other molecules, these different activities are 
also annotated. In the absence of additional evidence, it is cur-
rently impossible to highlight which GO term describes the in vivo 
function of the enzyme. For the reactions known to be implicated 
in vitamin K catabolism, adding this information as an annotation 
extension helps clarify the main role of that specifi c reaction ( see 
Chap.  17 , [ 6 ]). 
2.5  Main Functions 
and Secondary Roles
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 Our understanding of biology is dynamic, and evolves as new 
experiments confi rm or contradict previous results. It is therefore 
essential to read several, preferably recent publications on a subject 
to make sure that prior working hypotheses, that have subsequently 
been invalidated, are not annotated. That is, sometimes it is neces-
sary to remove annotations in order to limit the number of false 
positives. A number of mechanisms exist in GO to capture evolu-
tion of knowledge. New GO terms are added to the ontology 
when knowledge is not covered by existing GO terms. Curators 
work in collaboration with the GO editors, defi ning new terms or 
correcting the defi nitions of existing terms when required. 
Confl icting results can be dealt by using the “NOT” qualifi er, 
which states that a gene product is not associated with a GO term. 
This qualifi er is used when a positive association to this term could 
otherwise be expected from previous literature or automated 
methods (for more information read  www.geneontology.org/
GO.annotation.conventions.shtml#not ). 
 A good example of how GO deals with evolving knowledge as 
new papers are published on a protein is provided by the recent 
characterization of the NOTUM protein in human and  Drosophila 
melanogaster . Notum was fi rst characterized in  D. melanogaster 
(UniProtKB Q9VUX3) as an inhibitor of Wnt signaling [ 22 ,  23 ]. 
Based on its sequence similarity with pectin acetylesterase family 
members, it was initially thought to hydrolyze glycosaminoglycan 
(GAG) chains of glypicans by mediating cleavage of their GPI 
anchor in vitro [ 24 ]. Two different articles published recently con-
tradict these previous results, showing that the substrate of human 
NOTUM (UniProtKB Q6P988) and  D. melanogaster Notum is 
not glypicans, and that human NOTUM specifi cally mediates a 
palmitoleic acid modifi cation on WNT proteins [ 25 ,  26 ]. This new 
data confi rms the role of NOTUM as an inhibitor of Wnt  signaling, 
but with a mechanism completely different from what the initial 
studies had suggested. To correctly capture these fi ndings in GO, 
new terms describing protein depalmitoleylation were added in 
GO: “palmitoleyl hydrolase activity” (GO:1990699) and “protein 
depalmitoleylation” (GO:1990697). In addition, NOTUM pro-
teins received negative annotations for “GPI anchor release” 
(GO:0006507) and “phospholipase activity” (GO:0004620) to 
indicate that these fi ndings had been disproven. 
 Although relatively infrequent, this type of situation is critical 
because it may affect the accuracy of the GO. Ideally, when new 
fi ndings invalidate previous ones, old annotations are revisited in 
the light of new knowledge and annotation from previous papers 
reevaluated to ensure that annotation was not the result of over- 
interpretation of data. 
 The most widely used manual protein annotation editor 
for GO, Protein2GO, has a mechanism to dispute questionable 
or outdated annotations that sends a request for reevaluation 
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of annotations [ 27 ]. Users who notice incorrect or missing 
 annotations are strongly encouraged to notify the GO helpdesk 
( http://geneontology.org/form/contact-go ) so that corrections 
can be made. 
3  Importance of Annotation Consistency: Toward a Quality Control Approach 
 The goal of the GO project is to provide a uniform schema to 
describe biological processes mediated by gene products in all cel-
lular organisms [ 2 ]. Annotation involves translating conclusions 
from biological experiments into this schema, such that we are 
making inferences of inferences. To avoid deriving too much from 
the biologically relevant conclusions of experiments, consistent 
annotation within the GO framework is essential. 
 The GO curators make every effort to ensure that annotations 
refl ect the current state of knowledge. As new fi ndings are made 
that invalidate or refi ne existing models there is a need for course 
correction; otherwise both the ontology and the annotations 
may drift. 
 Over 20 groups contribute to manual annotations to the GO 
project ( http://geneontology.org/page/download-annotations ). 
The number of annotations by species, broken down into experi-
mental versus non-experimental, is shown in Fig.  3 . Since manual 
annotations are so critical to the overall quality of the entire corpus 
of GO data, it is important that each biocurator from every con-
tributing group interprets experiments consistently.
 Fig. 3  Number of annotations in 12 species annotated by the GO consortium. Source:  http://geneontology.org/
page/current-go-statistics 
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 While the GO Consortium does not possess suffi cient resources 
to review all annotations individually on an ongoing basis, several 
approaches are in place to ensure consistency:
 ●  GO uses automated procedures for validating GO annotations. 
An automated checker runs through the GO annotation 
 rulebase ( http://geneontology.org/page/annotation-quality- 
control-checks ), which validates the syntactic and biological 
content of the annotation database, and verifi es that correct 
procedures are followed. Examples include taxon checks [ 28 ] 
and checks to ensure that the correct object type is used with 
different types of evidence. 
 ●  The annotation team of the GO consortium also has regular 
annotation consistency exercises, where participating annota-
tors independently annotate the same paper to ensure that 
guidelines are applied in a uniform manner, discuss any dis-
crepancy, and update guidelines when these are lacking or need 
clarifi cation. 
 ●  Finally, the Reference Genome Project [ 29 ] has proven to be a 
very useful resource to improve annotation coherence across 
the GO (Feuermann et al.,  in preparation ). The project uses 
PAINT, a Phylogenetic Annotation and INference Tool, to 
annotate protein families from the PantherDB resource [ 30 ]. 
PAINT integrates phylogenetic trees, multiple sequence align-
ments, experimental GO annotations, as well as references 
pointing to the original data. PAINT curators select the high- 
confi dence data that can be propagated across either the entire 
tree or specifi c clades. By displaying different GO annotations 
for all members of a family, PAINT makes it easy to detect 
inconsistencies, thus improving the overall quality of the set of 
GO annotations. It also gives a mean of identifying consistent 
biases that usually indicate a problem in the ontology or in the 
annotation guidelines. 
4  Summary 
 Expert curation of GO terms based on experimental data is a com-
plex process that requires a number of skills from biocurators. In 
this chapter, we describe a number of guidelines to warn curators 
on common annotation mistakes and provide clues on how to 
avoid them. These simple rules, summarized in Table  2 , can be 
used as a checklist to ensure that GO annotations are in line with 
GO consortium guidelines.
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5  Perspective 
 The guidelines presented here are easy to follow and reinforce cura-
tion quality without reducing curation effi ciency, which is a serious 
and valid challenge in the era of big data. In view of the amount of 
data to be dealt with, it has often been argued that manual curation 
“just doesn’t scale,” and an ongoing search for alternative methods 
is under way in the world of biocuration and bioinformatics. 
However, examples described in this chapter show that most pub-
lications describe complex knowledge that cannot be captured by 
machine learning or text mining technologies. To continue having 
an acceptable throughput, manual curation should be able to cope 
with the increasing corpus of scientifi c data. From this perspective, 
PAINT constitutes an excellent example of a  propagation tool 
based on experimental GO annotations, which ensures maximum 
consistency and effi ciency without compromising the quality of the 
annotations produced. Such system provides one possible answer 
to the concerns addressed on scalability of expert curation. 
 Funding Open Access charges were funded by the University 
College London Library, the Swiss Institute of Bioinformatics, the 
Agassiz Foundation, and the Foundation for the University of 
Lausanne.
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the Creative Commons Attribution 4.0 International License 
 Table 2 
 Summary of annotation guidelines 
 Carefully select publications . 
 Only annotate papers that provide the most added value. 
 Read recent publications . 
 Research is not a straightforward process and reading recent publications helps resolving confl icts 
and detecting experimental discrepancies. 
 Check annotation consistency . 
 Review the existing annotations for related proteins to see whether the annotations you are adding are 
consistent. 
 Look for confi rmation for unusual fi ndings with multiple papers ,  if possible . 
 Avoid entering annotations based on experiments that do not directly implicate the protein with the 
GO term you annotate. 
 Annotate the conclusion of the experiment . 
 Keep in mind that this may be different from the results presented. Be especially careful of interpreting 
the function of proteins based on mutant phenotypes. 
 Remove obsolete annotations . 
 If you encounter an annotation that is based on an interpretation of an experiment that is no longer 
valid, use the Challenge mechanism or GO helpdesk to ask to have the annotation removed. 
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( http://creativecommons.org/licenses/by/4.0/ ), which permits 
use, duplication, adaptation, distribution and reproduction in any 
medium or format, as long as you give appropriate credit to the 
original author(s) and the source, a link is provided to the Creative 
Commons license and any changes made are indicated. 
 The images or other third party material in this chapter are 
included in the work’s Creative Commons license, unless indicated 
otherwise in the credit line; if such material is not included in the 
work’s Creative Commons license and the respective action is not 
permitted by statutory regulation, users will need to obtain per-
mission from the license holder to duplicate, adapt or reproduce 
the material. 
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